Large gap with delayed quotes
|
Last quote
11/04/2025
-
02:00:00
|
Bid
11/04/2025 -
12:32:54
|
Bid Volume |
Ask
11/04/2025 -
12:32:54
|
Ask Volume |
|---|---|---|---|---|
|
6.86
-0.46
(
-6.28% )
|
6.50
|
100 |
7.32
|
100 |
Analysis date: 31.10.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 31.10.2025.
Interest
Weak
Weak
Two stars since 17.10.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 14.10.2025 at a price of 6.42.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 27.06.2025.
4wk Rel Perf
-5.83%
-5.83%
The four-week dividend-adjusted underperformance versus SP500 is 5.83%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.54%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.23%.
Mkt Cap in $bn
1.54
1.54
With a market capitalization <$2bn, BIOCRYST PHARMA is considered a small-cap stock.
G/PE Ratio
10.01
10.01
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
8.09
8.09
The estimated PE is for the year 2029.
LT Growth
81.03%
81.03%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
8
8
Over the last seven weeks, an average of 8 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
66
66
For 1% of index variation, the stock varies on average by 0.66%.
Correlation
0.27
0.27
Stock movements are strongly independent of index variations.
Value at Risk
2.67
2.67
The value at risk is estimated at USD 2.67. The risk is therefore 36.43%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
16.09.2014
16.09.2014